TIDAL: Target-Induced Droplet Assembly of Ligands
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
TRIAD - DOE CONTRACTOR
Contract Value
Not provided
Codes & Classification
Solicitation Number
S-197478
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AJ11
Additional Details
The Department of Energy, through its contractor TRIAD at Los Alamos National Laboratory (LANL), has issued a Special Notice regarding the availability of a novel biotechnology platform known as TIDAL: Target-Induced Droplet Assembly of Ligands. This technology, developed at LANL, represents a significant advancement in the use of nanobodies—small antibody fragments—by transforming them into programmable, protein-only materials capable of self-assembly in response to specific molecular targets.
TIDAL leverages the natural phenomenon of liquid-liquid phase separation to enable nanobodies, when fused with an engineered encapsulation peptide (EP), to form dense, dynamic protein droplets upon encountering their intended target. This process is both reversible and tunable, allowing the droplets to serve multiple functions: as purification handles that eliminate the need for costly resins, as drug delivery vehicles that form slow-release depots in situ, and as intracellular traps that can sequester and neutralize harmful proteins within living cells. The technology is designed to lower production costs, simplify manufacturing processes, and expand the possibilities for therapeutic and diagnostic applications, all while utilizing biologically familiar building blocks.
Key features and advantages of TIDAL include:
- The ability to reduce protein purification costs by replacing traditional column resins with a simple, trigger-based precipitation step.
- Enabling patient-friendly, at-home drug delivery systems that remain liquid until administration and then form a slow-release depot.
- A fully protein-based system that avoids synthetic carriers, streamlining manufacturing and regulatory pathways.
- Functionality within living cells to trap and neutralize disease-associated proteins, such as those involved in cancer or viral infections.
- Enhanced diagnostic sensitivity by concentrating weak signals into easily detectable droplets.
- A versatile, adaptable platform suitable for a range of applications, including manufacturing, therapy, and detection.
The intended market applications for TIDAL span several sectors:
- Biopharmaceutical manufacturing (e.g., antibody and enzyme purification, protein production)
- Therapeutics and drug delivery (e.g., subcutaneous slow-release treatments, intracellular protein targeting)
- Diagnostics (e.g., high-sensitivity detection assays, point-of-care testing)
- Biotechnology (e.g., resin-free enzyme immobilization, biocatalysis)
- Reagents (e.g., protein capture, condensate-based cell studies)
The technology is currently at Technology Readiness Level (TRL) 3, indicating proof-of-concept has been demonstrated in a laboratory setting. A U.S. patent is pending (reference LA-UR-26-27937).
This notice is not a solicitation for external development services. Instead, LANL is seeking to engage with companies interested in licensing the TIDAL technology for commercial development. Both exclusive and non-exclusive licensing agreements are available, and the laboratory encourages inquiries from established firms as well as startups seeking to leverage this innovation to enhance their product offerings.
The procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with no set-aside restrictions. The place of performance is Los Alamos, New Mexico, United States.
Interested parties are encouraged to contact the LANL Technology Partnerships Office for further information and to discuss licensing opportunities. The primary and secondary contacts for this opportunity are Caleb Ledgerwood and Lindsay Augustyn, both reachable at [email protected]. Additional details about LANL’s licensing program and available technologies can be found at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology and m.lanl.gov/tech-search.
This Special Notice remains active, with a response deadline of September 12, 2026. For the full notice and any updates, refer to the official posting on SAM.gov (Opportunity ID: 746191550a8a4fd88b095e00c69968cc).